Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Recovery ⢠Strong Liquidity ⢠Persistent Losses GKOS's Q2 performance improved sharply with strong liquidity and positive cash flow, but ongoing losses, high spending, and premium valuation keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights: ⢠Short-Term Downtrend ⢠Emerging Support ⢠Key Breakout Level Support Level: $161â$163 Resistance Level: $171â$172 GKOS remains in a short-term downtrend after falling about 11% over the last month, with $161â$163 support and a move above $171â$172 needed to improve momentum.
Sentiment & News
Key News Insights: ⢠New Institutional Buying ⢠Major Fund Reductions ⢠Positive Price Momentum GKOS gained new major institutional buyers and rose 8% post-earnings, though sizable hedge-fund selling signals mixed investor conviction.
AI Summary
GKOS has evolved into a credible commercial ophthalmology platform with accelerating sales, expanding margins, and positive cash flow, but its ~15.6x sales valuation now requires Epioxa and iDose TR to achieve reimbursement-supported adoption and sustained operating leverageânot merely strong revenue growth. Investors should view the $161â$163 support range and paid-eye/reimbursement progress as key validation points; setbacks could trigger a meaningful valuation reset.
Description
Glaukos Corporation develops ophthalmic medical devices and pharmaceutical therapies for glaucoma, corneal conditions, and retinal diseases. Its commercial portfolio centers on micro-bypass stents placed with cataract surgery to improve aqueous outflow in patients with mild-to-moderate open-angle glaucoma, while its pipeline includes a multi-stent system for refractory cases and a micro-scale injectable implant for sustained drug delivery. The company sells through a combination of direct sales and distributors in the U.S. and internationally and is headquartered in San Clemente, California, having been incorporated in 1998.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | GKOS | Glaukos Corporation | Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20. | Closed | -1.6% |